All In Biotech

Free tool

FAERS Monitor: Hyftor

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213478 or its brand name (Hyftor, Sirolimus). Reports on generic versions are filed under their own applications.

Reports

13,673

Serious

11,686

85% of reports

Hospitalization

4,681

Death reported

2,174

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use2,127
  • drug ineffective1,149
  • product use in unapproved indication792
  • pyrexia533
  • diarrhoea530
  • pneumonia501
  • drug interaction450
  • acute kidney injury443
  • thrombotic microangiopathy386
  • transplant rejection384
  • cytomegalovirus infection355
  • condition aggravated320
  • nausea318
  • toxicity to various agents316
  • infection313

Reports by year received

View as table
YearReports
200441
200553
200651
2007232
2008194
2009294
2010152
2011253
2012231
2013204
2014239
2015315
2016425
2017598
2018845
2019990
20201,021
20211,054
20221,230
20231,170
20241,489
20251,583
20261,009

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,486 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
transplant rejectionSignal38477.469.927,497
thrombotic microangiopathySignal38663.457.322,719
cytomegalovirus infectionSignal35533.630.210,949
product use in unapproved indicationSignal7924.94.62,498
acute kidney injurySignal4434.54.11,192
drug interactionSignal4504.44.01,173
off label useSignal2,1273.73.64,448
infectionSignal3133.33.0511
toxicity to various agentsSignal3162.92.6390
pneumoniaSignal5012.42.2406
pyrexiaSignal5332.42.2428
condition aggravated3201.61.576
drug ineffective1,1491.31.3106
diarrhoea5301.31.230
nausea3180.60.678

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.